Bevacizumab — knowledge graph · CancerIndex

Knowledge graph · Drug

Bevacizumab

monoclonal antibody

Identifier: CI-DRUG-00000107
Entity page: /drug/bevacizumab ↗
Edges: 2,512

Neighbours: 30 cancers1 genes11 variants10 trials43 approvals
Drawn: 60 of 95 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bevacizumab approved for …APPROVED_FOR66 of 43show fewer
→ approved for	Hepatocellular Carcinomasubtype	supports	FDA ORIG	Hepatocellular Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Malignant Peritoneal Neoplasmsubtype	supports

→ approved for

EMA · EU · 2022VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. VEGZELMA in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. VEGZELMA in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with VEGZELMA in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. VEGZELMA, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (NSCLC) other than predominantly squamous cell histology. VEGZELMA, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). VEGZELMA, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. VEGZELMA, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). VEGZELMA, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor–targeted agents. VEGZELMA in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). VEGZELMA, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2022-08-17 · VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of …

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2021-04-21 · Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of th…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Alymsys in combination with capecitabine. Alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · approved · 2021-03-26 · Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of t…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Oyavas in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see Section 5.1). Oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2021-03-26 · Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of th…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Onbevzi in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · withdrawn · 2021-01-11 · Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of t…

—

withdrawn

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2020Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · withdrawn · 2020-09-24 · Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma …

—

withdrawn

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2020Aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1 of the SmPC. Aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Aybintio in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1 of the SmPC. Aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1 of the SmPC). Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1 of the SmPC). Aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see section 5.1 of the SmPC). Aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1 of the SmPC).

EMA (EU) · approved · 2020-08-19 · Aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of …

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2018Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · approved · 2018-01-15 · Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2005Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine. For further information as to HER2 status. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · approved · 2005-01-12 · Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma …

—

approved

not mapped

Regulatory

ema

open ↗

Bevacizumab predicts response to …PREDICTS_RESPONSE_TO12 of 12
← predicts response to	MMP2 SERUM LEVELS 2 source records aggregated	sensitivity	B	Breast Inflammatory Carcinoma	2	Curated	civic	graph →
← predicts response to	PPP1R15A RS557806SNV	sensitivity	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	IDH1 R132	sensitivity	B	High-Grade Glioma, NOS	1	Curated	civic	graph →
← predicts response to	EPHB4 EXPRESSIONexpression	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	EGFR Exon 18 Overexpressionexpression	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	VEGFA Decreased Peri-therapeutic Expressionexpression	sensitivity	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF Mutationother	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF V600ESNV	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	MMP9 SERUM LEVELS	resistance	B	Breast Inflammatory Carcinoma	1	Curated	civic	graph →
← predicts response to	KRAS Mutationother	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF Fusionfusion 2 source records aggregated	sensitivity	C	Spindle Cell Sarcoma	2	Curated	civic	graph →
← predicts response to	BRAF V600ESNV	sensitivity	D	Malignant Colorectal Neoplasm	1	Curated	civic	graph →

Bevacizumab investigated for …INVESTIGATED_FOR15 of 109show all (up to 200)
→ investigated for	Malignant Colorectal Neoplasmsubtype 6 source records aggregated	supports	B	Malignant Colorectal Neoplasm	6	Curated	civic	graph →
→ investigated for	Breast Inflammatory Carcinomasubtype 2 source records aggregated	supports	B	Breast Inflammatory Carcinoma	2	Curated	civic	graph →
→ investigated for	High-Grade Glioma, NOSsubtype	supports	B	High-Grade Glioma, NOS	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Fallopian Tube Neoplasmsubtype	unknown	4	Fallopian Tube Neoplasm	1	Curated	chembl	graph →
→ investigated for	Colon Neoplasmsubtype	unknown	4	Colon Neoplasm	1	Curated	chembl	graph →
→ investigated for	Peritoneal Neoplasmcancer_family	unknown	4	Peritoneal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Cervical Neoplasmsubtype	unknown	4	Cervical Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	4	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	4	Renal Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Glioblastomasubtype	unknown	4	Glioblastoma	1	Curated	chembl	graph →
→ investigated for	Colorectal Neoplasmsubtype	unknown	4	Colorectal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →

Bevacizumab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 526show all (up to 200)
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 315 trials (89 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	315	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 146 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	146	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 144 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	144	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 110 trials (46 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	110	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastomasubtype 107 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 105 trials (62 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasmsubtype 63 trials (22 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	63	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Fallopian Tube Neoplasm 61 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Fallopian Tube Neoplasm	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 61 trials (35 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 57 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 57 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinomasubtype 52 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 47 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 46 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Rectal Neoplasm 45 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Rectal Neoplasm	45	Observed	clinicaltrials	graph →

Bevacizumab studied in …STUDIED_INderived10 of 1,821show all (up to 200)
→ studied in	NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · 1,821 trials list this drug (445 active)	—	—	Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · 1,821 trials list this drug (445 active)	—	—	Hereditary Leiomyomatosis and Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06890338Phase 2 · recruiting A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · 1,821 trials list this drug (445 active)	—	—	Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07198074Phase 3 · recruiting Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · 1,821 trials list this drug (445 active)	—	—	Endometrial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07278336Phase 1 · recruiting A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer · 1,821 trials list this drug (445 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07446322Phase 2 · recruiting FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer · 1,821 trials list this drug (445 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · 1,821 trials list this drug (445 active)	—	—	Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07756840Phase 2 · not yet recruiting Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) · 1,821 trials list this drug (445 active)	—	—	Respiratory System Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 1,821 trials list this drug (445 active)	—	—	Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 1,821 trials list this drug (445 active)	—	—	Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths